Let’s Talk Medtech

A look at what's in store for medtech deals this year. Will 2022 be known as the year of Medtech M&A? Looks like it. EY's John Babitt joins us for a riveting conversation about EY's Annual M&A Firepower Report.

Omicron has caused quite a disruption in both pharma and medtech. Derron Stark EY-Parthenon Partner, Principal, Strategy Transactions, speaks about these supply chain issues.

Dr. Lishan Aklog wears multiple hats. He's the CEO of both PavMed and Lucid Diagnostics. Being a CEO of two companies during the pandemic can be tough at times, but Dr. Aklog's biggest challenge is getting out the awareness of how some instances of GERD can lead to Esophageal Cancer.

Dr. Aklog stops by for an amazing conversation on how Lucid Diagnostics is making an impact in the detection of Esophageal Cancer.

Paul Grand, MTI's CEO and Glenn Synder, Deloitte's Principle medtech practice leader discuss startups.

A look at what means to be a person of color in the medtech industry.

Marissa Fayer is a decorated veteran of medtech. Hear how she broke into the industry and how she founded HERHealthEQ to fight for women's health.

PwC's Glenn Hunzinger stops by to discuss the  Pharmaceutical and life sciences deals insights: 2021 midyear outlook report, showcasing the PLS sector returned to normal deal activity with strong deal volume. Plus, Omar Ford, MD+DI's Managing Editor gives his take on the controversial Illumina/Grail merger.